{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-25-000057","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.674881+00:00","generated_at":"2026-05-21T10:49:39.688298+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inhibrx Q1 net loss $43.3M; cash $216.5M after $100M loan; data readouts expected in 2025","bullets":["Net loss $43.3M ($2.80/share) vs $78.7M ($5.77/share) in Q1 2024.","Cash $216.5M at March 31, 2025, up from $152.6M after $100M loan from Oxford Finance in Jan 2025.","INBRX-109 registration-enabling Phase 2 data for chondrosarcoma expected Q3 2025; CRC cohort data also Q3 2025.","INBRX-106 Phase 2/3 data for HNSCC with Keytruda expected Q4 2025; interim NSCLC data Q4 2025.","R&D expenses fell to $36.9M from $63.9M due to spin-off of INBRX-101 program in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-25-000057","json":"https://secwatch.observer/filing/0002007919-25-000057.json","markdown":"https://secwatch.observer/filing/0002007919-25-000057.md","text":"https://secwatch.observer/filing/0002007919-25-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791925000057/0002007919-25-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791925000057/inhibrx-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:49:39.688298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}